These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25824150)

  • 1. Preemptive antiretroviral therapy modifications for the management of potential clinically significant drug interactions with direct acting hepatitis C therapies.
    Stambough M; Roman M; Blair DC; Sidman EF; Miller CD
    Int J STD AIDS; 2016 Mar; 27(3):235-7. PubMed ID: 25824150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing treatment in HIV/HCV coinfection.
    Puoti M; Rossotti R; Travi G; Panzeri C; Morreale M; Chiari E; Cocca G; Orso M; Moioli MC
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S355-62. PubMed ID: 24091116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A switch to Raltegravir improves antiretroviral associated hepatotoxicity in individuals co-infected with HIV and hepatitis C.
    Cevik M; Katsarolis I; Singh GJ; Nelson M
    J Infect; 2014 Aug; 69(2):190-3. PubMed ID: 24793307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.
    Rockstroh JK
    Liver Int; 2015 Jan; 35 Suppl 1():51-5. PubMed ID: 25529087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection.
    Karageorgopoulos DE; El-Sherif O; Bhagani S; Khoo SH
    Curr Opin Infect Dis; 2014 Feb; 27(1):36-45. PubMed ID: 24305043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response.
    Bani-Sadr F; Loko MA; Pambrun E; Winnock M; Carrieri P; Gilbert C; Duvivier C; Bouchaud O; Gervais A; Dabis F; Salmon D;
    AIDS; 2014 May; 28(8):1155-60. PubMed ID: 24499953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals.
    Klein MB; Rollet KC; Hull M; Cooper C; Walmsley S; Conway B; Pick N;
    Antivir Ther; 2013; 18(5):717-21. PubMed ID: 23211632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevalence of potential interactions between antiretroviral therapy and boceprevir or telaprevir in human immunodeficiency virus-hepatitis C virus coinfected patients].
    González-Colominas E; Solà R; Barrantes-González M; Salas E
    Enferm Infecc Microbiol Clin; 2013 May; 31(5):350-1. PubMed ID: 23182365
    [No Abstract]   [Full Text] [Related]  

  • 9. Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals.
    Cope R; Pickering A; Glowa T; Faulds S; Veldkamp P; Prasad R
    AIDS Patient Care STDS; 2015 Jul; 29(7):379-83. PubMed ID: 26066094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
    Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
    HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug interactions of hepatitis C direct-acting antivirals in the HIV-infected person.
    El-Sherif O; Back D
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):336-43. PubMed ID: 26159742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.
    Mandorfer M; Payer BA; Niederecker A; Lang G; Aichelburg MC; Strassl R; Boesecke C; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
    AIDS Patient Care STDS; 2014 May; 28(5):221-7. PubMed ID: 24796757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; McNicholl IR
    Pharmacotherapy; 2011 Apr; 31(4):357-68. PubMed ID: 21449625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
    Neuman MG; Monteiro M; Rehm J
    Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
    Rockstroh J; Teppler H; Zhao J; Sklar P; Harvey C; Strohmaier K; Leavitt R; Nguyen BY
    HIV Med; 2012 Feb; 13(2):127-31. PubMed ID: 21599819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs.
    Puoti M; Panzeri C; Rossotti R; Baiguera C
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S206-11. PubMed ID: 25458781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals.
    Zeremski M; Martinez AD; Talal AH
    Clin Infect Dis; 2014 Mar; 58(6):880-2. PubMed ID: 24336913
    [No Abstract]   [Full Text] [Related]  

  • 20. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals.
    Taramasso L; Madeddu G; Ricci E; De Socio GV; Menzaghi B; Orofino G; Passerini S; Franzetti M; Maggi P; Dentone C; Martinelli C; Celesia BM; Penco G; Libertone R; Quirino T; Bonfanti P; Di Biagio A;
    Biomed Pharmacother; 2015 Feb; 69():233-6. PubMed ID: 25661363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.